Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.

Sytske Anne BergstraCornelia F AllaartRosaline van den BergArvind ChopraNimmisha GovindTom W J HuizingaRobert B M Landewe

Published in: Arthritis research & therapy (2017)

In patients newly diagnosed with RA, no clinical benefit of high compared to low initial MTX doses was found for MTX monotherapy or for MTX combination therapy with csDMARDs or glucocorticoids.

Keyphrases

combination therapy
newly diagnosed
high dose
low dose
end stage renal disease
ejection fraction
chronic kidney disease
stem cell transplantation
prognostic factors
patient reported outcomes
disease activity
systemic lupus erythematosus
study protocol